What a terrilble joke.
Beacuse of GSK failure to support IV relenza the US govt gave Biocryst uo to $100 million to develop this IV drug. Short needle long needle.
However you look at it its a failure. Biocryst shareprice has gone through he floor bigtime.
US taxpayers backed a dud all because of GSK lack of interest.
Its enough to make a shareholder cry.
peramivir disappoints in results, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)